GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507085 | Stomach | GC | regulation of protein secretion | 33/1159 | 268/18723 | 1.27e-04 | 2.40e-03 | 33 |
GO:00512226 | Stomach | GC | positive regulation of protein transport | 36/1159 | 303/18723 | 1.33e-04 | 2.49e-03 | 36 |
GO:00328724 | Stomach | GC | regulation of stress-activated MAPK cascade | 26/1159 | 192/18723 | 1.40e-04 | 2.59e-03 | 26 |
GO:00703024 | Stomach | GC | regulation of stress-activated protein kinase signaling cascade | 26/1159 | 195/18723 | 1.81e-04 | 3.13e-03 | 26 |
GO:00310985 | Stomach | GC | stress-activated protein kinase signaling cascade | 30/1159 | 247/18723 | 3.20e-04 | 5.10e-03 | 30 |
GO:0003081 | Stomach | GC | regulation of systemic arterial blood pressure by renin-angiotensin | 7/1159 | 23/18723 | 3.48e-04 | 5.49e-03 | 7 |
GO:00431224 | Stomach | GC | regulation of I-kappaB kinase/NF-kappaB signaling | 30/1159 | 249/18723 | 3.67e-04 | 5.70e-03 | 30 |
GO:00514035 | Stomach | GC | stress-activated MAPK cascade | 29/1159 | 239/18723 | 4.06e-04 | 6.18e-03 | 29 |
GO:00610285 | Stomach | GC | establishment of endothelial barrier | 10/1159 | 46/18723 | 4.18e-04 | 6.32e-03 | 10 |
GO:0060326 | Stomach | GC | cell chemotaxis | 35/1159 | 310/18723 | 4.34e-04 | 6.46e-03 | 35 |
GO:0003094 | Stomach | GC | glomerular filtration | 7/1159 | 25/18723 | 6.12e-04 | 8.28e-03 | 7 |
GO:0002687 | Stomach | GC | positive regulation of leukocyte migration | 19/1159 | 135/18723 | 6.56e-04 | 8.76e-03 | 19 |
GO:0070661 | Stomach | GC | leukocyte proliferation | 35/1159 | 318/18723 | 6.92e-04 | 9.20e-03 | 35 |
GO:00508786 | Stomach | GC | regulation of body fluid levels | 40/1159 | 379/18723 | 6.92e-04 | 9.20e-03 | 40 |
GO:00031585 | Stomach | GC | endothelium development | 19/1159 | 136/18723 | 7.19e-04 | 9.47e-03 | 19 |
GO:00972053 | Stomach | GC | renal filtration | 7/1159 | 26/18723 | 7.94e-04 | 1.01e-02 | 7 |
GO:0032612 | Stomach | GC | interleukin-1 production | 18/1159 | 128/18723 | 9.08e-04 | 1.11e-02 | 18 |
GO:0032652 | Stomach | GC | regulation of interleukin-1 production | 18/1159 | 128/18723 | 9.08e-04 | 1.11e-02 | 18 |
GO:00328734 | Stomach | GC | negative regulation of stress-activated MAPK cascade | 10/1159 | 51/18723 | 9.90e-04 | 1.18e-02 | 10 |
GO:00703034 | Stomach | GC | negative regulation of stress-activated protein kinase signaling cascade | 10/1159 | 51/18723 | 9.90e-04 | 1.18e-02 | 10 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2R | SNV | Missense_Mutation | | c.978N>G | p.Phe326Leu | p.F326L | P25116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
F2R | SNV | Missense_Mutation | | c.253N>A | p.Pro85Thr | p.P85T | P25116 | protein_coding | tolerated(0.39) | benign(0.005) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2R | SNV | Missense_Mutation | novel | c.1106N>C | p.Leu369Pro | p.L369P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AO-A0JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
F2R | SNV | Missense_Mutation | | c.250N>T | p.Leu84Phe | p.L84F | P25116 | protein_coding | tolerated(0.69) | benign(0.063) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
F2R | SNV | Missense_Mutation | | c.238N>G | p.Leu80Val | p.L80V | P25116 | protein_coding | tolerated(0.55) | benign(0.039) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
F2R | insertion | Frame_Shift_Ins | novel | c.391_392insACACTACCAGGCTCTGCTCTGCTGTCTCTGAGTTGGTACTACTC | p.Met131AsnfsTer16 | p.M131Nfs*16 | P25116 | protein_coding | | | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
F2R | SNV | Missense_Mutation | | c.299N>C | p.Trp100Ser | p.W100S | P25116 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
F2R | SNV | Missense_Mutation | novel | c.727N>C | p.Thr243Pro | p.T243P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P25116 | protein_coding | tolerated(0.57) | benign(0.096) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | | c.1210N>G | p.Met404Val | p.M404V | P25116 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | inhibitor | CHEMBL2013119 | RIGOSERTIB SODIUM | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | TYROSINE KINASE INHIBITOR | | 15383630 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | MORPHINE | MORPHINE | 12373743 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | ETHANOL | ALCOHOL | 16930224 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 405560412 | | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2103856 | ATOPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2107386 | VORAPAXAR SULFATE | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | WORTMANNIN | WORTMANNIN | 10318860,7559410,8955143 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 178100871 | VORAPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178100667 | | |